Blurriness of vision points toward damage to retina. Medical conditions have always been treated effectively with the administration and uses of herbs. Increase in venous pressure also causes bursting of blood vessels in eye. http://www.allsaintsportsmouth.us/experteyedoctor/2016/12/05/the-best-questions-for-deciding-upon-details-in-eye-surgery/So, it is very important to detect and treat this condition in the primary stages. Certain drugs and medications also influence the intra ocular pressure. This article provides some information about the various possible causes of black spots in vision that might prove beneficial. People with known health problems such as diabetes, heart diseases should not ignore this condition. Blurring of vision and/or seeing haloes It is possible that some people experience intermittent attacks of angle closure, where the angle does not get closed completely. The basic function of this fluid is to maintain pressure in the eye, known as intra ocular eye pressure. But, if it is a severe case, surgery is the only treatment. no dataBeta blockers like Timolol decrease the production of fluid, whereas prostaglandin analogy like Travatan®, Xalatan®, and Lumigan® raise the level of fluid flowing out from the eye.
As announced on 16 May 2016, Olli-Pekka Salovaara, Revenio Group Corporation`s long-term President & CEO resigned on 31 December 2016. At the same time, he resigned from board membership in the above-mentioned subsidiaries. Timo Hilden, who assumed the position of the Group`s new President & CEO on 1 January 2017 and has been a deputy member on the boards of Icare Finland Oy, Revenio Research Oy and Done Medical Oy will become an ordinary member of these boards, and Robin Pulkkinen, the Group`s CFO, will be appointed a deputy member of the boards. Tomi Karvo, Icare Finland Oy`s Sales and Marketing Director, has been appointed a new member of Oscare Medical Oy`s Board of Directors, and Timo Hilden has been appointed Chairman of the Board of Directors. Revenio Group Corporation www.revenio.fi The Revenio Group in brief Revenio is a Finnish, globally operating health technology corporation whose worldwide success is based on a strongly patented intraocular pressure measurement technology. The Revenio Group consists of Icare Finland Oy, Revenio Research Oy and Oscare Medical Oy, in which Revenio holds a 53% interest. The common denominators of Revenio`s business operations include screening, follow-up and the global need to make cost savings through preventive health care. Revenio seeks vigorous growth in health technology. Revenio aims to develop even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The focus of Revenio`s screening technology is on the early detection of glaucoma, osteoporosis, skin cancer and asthma, and the monitoring of these during the treatment process.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/revenio-group-corporation-changes-boards-130100005.html